Additionally, Panobinostat has shown potential in combination with Trastuzumab for the treatment of HER2-positive metastatic breast cancer and demonstrated therapeutic potential against aggressive triple-negative breast cancer cells (45, 46). Here, ERBB2 is linked to triple-negative breast carcinoma.